MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

Search

Grifols SA

Deschisă

SectorFinanțe

8.488 0.71

Rezumat

Modificarea prețului

24h

Curent

Minim

8.42

Maxim

8.564

Indicatori cheie

By Trading Economics

Venit

17M

69M

Vânzări

183M

2B

P/E

Medie Sector

36.313

20.525

EPS

0.101

Marjă de profit

3.491

Angajați

23,833

EBITDA

57M

482M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+65.92% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

1.6B

5.2B

Deschiderea anterioară

7.78

Închiderea anterioară

8.488

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

Grifols SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 apr. 2025, 17:19 UTC

Achiziții, Fuziuni, Preluări

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 apr. 2025, 13:02 UTC

Achiziții, Fuziuni, Preluări

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 apr. 2025, 10:13 UTC

Achiziții, Fuziuni, Preluări

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8 iul. 2024, 10:40 UTC

Achiziții, Fuziuni, Preluări

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8 iul. 2024, 09:13 UTC

Achiziții, Fuziuni, Preluări

Grifols Faces Delisting Bid From Founding Family and Brookfield

15 apr. 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2 apr. 2025, 09:27 UTC

Acțiuni populare

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Comparație

Modificare preț

Grifols SA Așteptări

Obiectiv de preț

By TipRanks

65.92% sus

Prognoză pe 12 luni

Medie 14.02 EUR  65.92%

Maxim 19.05 EUR

Minim 11 EUR

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGrifols SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

8.006 / 8.544Suport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.